Theravance Biopharma (TBPH) Total Debt (2018 - 2022)
Theravance Biopharma (TBPH) posted quarterly Total Debt of $396.1 million for Q2 2022, up 3.69% year-over-year from $382.0 million in Q2 2021, and up 0.75% quarter-over-quarter from $393.2 million in Q1 2022.
Theravance Biopharma (TBPH) Total Debt (2018 - 2022) Analysis & Trends
Theravance Biopharma (TBPH) has reported Total Debt for 5 consecutive years, with $396.1 million the latest figure, recorded in Q2 2022.
- In Q2 2022, Total Debt rose 3.69% year-over-year to $396.1 million; the TTM figure through Jun 2022 stood at $396.1 million (up 3.69% YoY), while the FY2021 annual figure was $388.3 million, down 1.0% from the prior year.
- Total Debt advanced to $396.1 million in Q2 2022 per TBPH's latest filing, from $393.2 million in the prior quarter.
- Across five years, Total Debt topped out at $396.1 million in Q2 2022 and bottomed at $229.2 million in Q4 2019.
- Historically, Total Debt has averaged $334.0 million across 5 years, with a median of $382.0 million in 2021.
- Annual changes were most pronounced in 2020 — Total Debt soared 71.16% — and 2021, when it retreated 1.0%.
- Theravance Biopharma's Total Debt stood at $229.5 million in 2018, then declined by 0.17% to $229.2 million in 2019, then jumped by 71.16% to $392.2 million in 2020, then fell by 1.0% to $388.3 million in 2021, then advanced by 2.02% to $396.1 million in 2022.
- Business Quant data shows TBPH's Total Debt at $396.1 million in Q2 2022, $393.2 million in Q1 2022, and $388.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 396.13 Mn |
| Mar 31, 2022 | 393.17 Mn |
| Dec 31, 2021 | 388.30 Mn |
| Sep 30, 2021 | 388.10 Mn |
| Jun 30, 2021 | 382.01 Mn |
| Mar 31, 2021 | 386.84 Mn |
| Dec 31, 2020 | 392.21 Mn |
| Sep 30, 2020 | 384.48 Mn |
| Jun 30, 2020 | 375.27 Mn |
| Mar 31, 2020 | 373.85 Mn |
| Dec 31, 2019 | 229.15 Mn |
| Sep 30, 2019 | 230.71 Mn |
| Jun 30, 2019 | 230.06 Mn |
| Mar 31, 2019 | 229.70 Mn |
| Dec 31, 2018 | 229.54 Mn |